Semax (10mg)

Description

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of ACTH(4-7) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike its parent sequence, Semax lacks the hormone activity of full-length ACTH and instead acts through mechanisms involving BDNF upregulation and serotonin/dopamine system modulation, making it a widely studied neuroprotective and cognitive research compound in Eastern European neuropharmacology.

Why Researchers Select Semax

Semax stimulates BDNF (Brain-Derived Neurotrophic Factor) expression in the hippocampus and prefrontal cortex in rodent models, with downstream effects on synaptic plasticity, neurogenesis, and cognitive function. It also modulates the serotonergic and dopaminergic systems and has demonstrated neuroprotective effects in ischemic brain injury models. As one of the few ACTH-derived peptides with extensive neuropharmacological research (particularly from Russian and Ukrainian literature), it provides a defined tool for studying ACTH fragment-BDNF-cognitive axis interactions.

Common Research Applications

• BDNF expression and hippocampal neurotrophin research
• Cognitive function and synaptic plasticity studies
• Neuroprotection in stroke/ischemia animal models
• Dopaminergic and serotonergic system modulation research
• ACTH peptide fragment bioactivity studies

Molecular Profile

• Sequence: Met-Glu-His-Phe-Pro-Gly-Pro | MW: ~813.9 g/mol | Purity: ≥98% HPLC

For Research Use Only. Not for human or veterinary use.